Skip to content
Screener

EyePoint, Inc. EYPT Financing Cash Flow

Financing Cash Flow at other companies

Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$619K+399%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$11.48M

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net settlement of stock units to satisfy statutory tax withholding(3,482)(1,237)
Proceeds from exercise of stock options and employee stock purchase plan1,684866
Principal payments on finance lease obligations(57)(51)
Net cash (used in) provided by financing activities17,378(713)
Net (decrease) increase in cash, cash equivalents and restricted cash8,637(28,561)
Cash, cash equivalents and restricted cash at beginning of period101,97199,854
Cash, cash equivalents and restricted cash at end of period$110,608$71,293
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s financing cash flow?
EyePoint, Inc. (EYPT) reported financing cash flow of $19.99M in Q2 2026.
How has EyePoint, Inc.'s financing cash flow changed year-over-year?
EyePoint, Inc.'s financing cash flow increased by 8300.0% year-over-year, from $238K to $19.99M.
What is the long-term trend for EyePoint, Inc.'s financing cash flow?
Over 3 years (2022 to 2025), EyePoint, Inc.'s financing cash flow has grown at a 466.6% compound annual growth rate (CAGR), from -$954.5K to $173.65M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about EyePoint, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude